New board appointment

Hikma Pharmaceuticals Plc
12 December 2006



                    Appointment of Non-executive Director

London, 12 December 2006 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) (the
'Company') is pleased to announce today's appointment of Dr Ronald L. Goode as
an independent non-executive director of the Company.

Commenting on the appointment, Samih Darwazah, Hikma's Chairman and Chief
Executive said, 'Ron will be an excellent addition to the Board as he brings
experience of multiple board appointments, corporate governance, strategic
development and public company issues. His pharmaceutical and financial
experience will be of significant value as we continue to build our business
both organically and through acquisitions and I am delighted that we have
attracted a businessman of his calibre and experience.'

During his career in the pharmaceutical industry, Dr. Goode has developed
expertise in operations on a global basis. He held key management positions at
Pfizer Pharmaceuticals (Vice President of Clinical Research and Scientific
Affairs, Director of Marketing Research) and at G. D. Searle & Co. (Senior Vice
President of Commercial Development, President of Asia/Pacific World Area,
President of Searle International Operations). He has an extensive record of
success in business development, and has supervised clinical development
programs that led to the filing of over a dozen New Drug Approval applications,
including Pfizer's Procardia XL(R) and Searle's Ambien(R). Dr. Goode has
previously served as President and Chief Executive Officer of two public
companies, Unimed Pharmaceuticals, Inc. and eXegenics Inc., and as a Director of
several other companies, including Hokuriku Seiyaku KK and Vitro Diagnostics.

Dr. Goode currently serves on the Board of Directors of Genitope Corporation and
is on the Advisory Board of ART Recherches et Technologies Avancees Inc., a
Canadian public medical devices company. He has also formed his own consulting
company, The Goode Group, for the purpose of advising Boards of Directors, CEOs,
investment funds, and private individuals. Dr. Goode is a director of Mercy
Ships International, a private charity, and is a trustee of Thunderbird, the
Garvin School of International Management.

Dr. Goode holds a M.S. in microbiology from the University of Memphis and a
Ph.D. in microbial genetics from the University of Georgia. In addition to his
general responsibilities as a non-executive director, Dr Goode will sit on both
the Audit and Remuneration committees of the Board.

                                    - ENDS -
Enquiries:


Hikma Pharmaceuticals PLC                               [phone]
Susan Ringdal, Investor Relations Director

Brunswick Group LLP                                     [phone]
Jon Coles / Justine McIlroy / Alex Tweed

Notes to Editors

About Hikma
Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed pharmaceutical products. Hikma's operations
are conducted through three businesses: Generic, Branded and Injectable
Pharmaceuticals. Hikma's operations are based principally in the United States,
the Middle East and North Africa ('MENA') region and Europe. In 2005, the Group
had revenue of $262 million and profit attributable to shareholders of $44
million. At 31 December 2005, the Group had over 1,800 employees. For news and
other information, please visit www.hikma.com.

Regulatory

There are no other details in respect of this appointment that are relevant to
be disclosed pursuant to the Listing Rules of the Financial Services Authority
or the Offered Securities Rules of the Dubai Financial Services Authority. Dr
Goode's appointment was made with the assistance of external recruitment
consultants with specific experience in the global pharmaceutical sphere.




                      This information is provided by RNS
            The company news service from the London Stock Exchange